We are live on
!
Find out more
YIH
Y-Intercept (HK) Portfolio holdings
AUM
$5.05B
1-Year Est. Return
17.89%
This Fund
S&P 500
This Quarter
Est. Return
+6.33%
1 Year Est. Return
+17.89%
3 Year Est. Return
+34.37%
5 Year Est. Return
+20.59%
10 Year Est. Return
–
AUM
$1.33B
AUM Growth
+$253M
(+24%)
Cap. Flow
+$204M
Cap. Flow
% of AUM
15.35%
Top 10 Holdings %
Top 10 Hldgs %
6.81%
Holding
1,856
New
682
Increased
391
Reduced
238
Closed
544
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
General Motors
GM
|
+$11.1M |
| 2 |
RTX Corp
RTX
|
+$7.48M |
| 3 |
Whirlpool
WHR
|
+$7.35M |
| 4 |
Illinois Tool Works
ITW
|
+$7.03M |
| 5 |
Adobe
ADBE
|
+$6.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$12.3M |
| 2 |
NVIDIA
NVDA
|
+$10.8M |
| 3 |
Microsoft
MSFT
|
+$10.7M |
| 4 |
Motorola Solutions
MSI
|
+$7.95M |
| 5 |
Apple
AAPL
|
+$7.75M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 17.39% |
| 2 | Consumer Discretionary | 14.49% |
| 3 | Industrials | 14.29% |
| 4 | Technology | 12.79% |
| 5 | Healthcare | 10.48% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1301
Savara
SVRA
$1.11B
| $58.8K | ﹤0.01% |
+11,803
| New | +$57K |
|
1302
Caribou Biosciences
CRBU
$158M
| $53.4K | ﹤0.01% |
+10,385
| New | +$64K |
|
|
CLSD
1303
DELISTED
Clearside Biomedical
CLSD
| $52.2K | ﹤0.01% |
+2,275
| New | +$49K |
|
|
ESPR
1304
DELISTED
Esperion Therapeutics
ESPR
| $49K | ﹤0.01% |
18,267
-9,002
| -33% | -$21.9K |
|
1305
Caesarstone
CSTE
$75.7M
| $45.7K | ﹤0.01% |
11,163
-2,859
| -20% | -$11.7K |
|
1306
Lumen
LUMN
$6.45B
| $44K | ﹤0.01% |
+28,213
| New | +$44.1K |
|
1307
Clover Health Investments
CLOV
$2.25B
| $38.5K | ﹤0.01% |
48,444
-20,265
| -29% | -$18.4K |
|
|
FLG
1308
Flagstar Bank National Association
FLG
$5.74B
| $38.2K | ﹤0.01% |
+3,953
| New | +$73.1K |
|
1309
RLX Technology
RLX
$2.49B
| $33.8K | ﹤0.01% |
17,619
-28,537
| -62% | -$54.6K |
|
1310
American Resources Corp
AREC
$188M
| $33.3K | ﹤0.01% |
23,585
-13,398
| -36% | -$19.8K |
|
1311
Opendoor
OPEN
$3.71B
| $32K | ﹤0.01% |
+10,918
| New | +$34.1K |
|
1312
Galectin Therapeutics
GALT
$223M
| $26.6K | ﹤0.01% |
+11,140
| New | +$21.1K |
|
1313
iShares MSCI All Country Asia ex Japan ETF
AAXJ
$3.66B
| – | – |
-12,911
| Closed | -$859K |
|
1314
AbbVie
ABBV
$454B
| – | – |
-6,943
| Closed | -$1.08M |
|
1315
Absci
ABSI
$1.28B
| – | – |
-20,807
| Closed | -$87.4K |
|
1316
Arch Capital
ACGL
$36.3B
| – | – |
-22,443
| Closed | -$1.67M |
|
1317
Axcelis
ACLS
$3.94B
| – | – |
-5,091
| Closed | -$660K |
|
|
ACRE
1318
Ares Commercial Real Estate
ACRE
$257M
| – | – |
-18,886
| Closed | -$196K |
|
1319
ACV Auctions
ACVA
$1.4B
| – | – |
-11,626
| Closed | -$176K |
|
1320
American Financial Group
AFG
$12B
| – | – |
-9,252
| Closed | -$1.1M |
|
1321
AGCO
AGCO
$8.71B
| – | – |
-9,826
| Closed | -$1.19M |
|
|
AGEN
1322
Agenus
AGEN
$255M
| – | – |
-5,205
| Closed | -$86.2K |
|
1323
Alamos Gold
AGI
$12.5B
| – | – |
-35,986
| Closed | -$485K |
|
1324
Agilysys
AGYS
$2.91B
| – | – |
-5,716
| Closed | -$485K |
|
1325
Applied Industrial Technologies
AIT
$12.9B
| – | – |
-4,678
| Closed | -$808K |
|
Similar funds
HSA
O
LIM
LFG
JIM
CTC
NL
BPWM
Y-Intercept (HK)'s Q1 2024 Portfolio in Review
As of Q1 2024, Y-Intercept (HK) held 1,856 positions worth $1.33B, up 24% from $1.07B the previous quarter. Its ten largest holdings account for 6.8% of the portfolio.
Y-Intercept (HK) deployed $204M of net new capital in Q1 2024, opening 682 new positions and adding to 391 existing holdings. Its largest new stake was General Motors: 287,173 shares worth $13M.
By sector, the portfolio is most concentrated in Financials at 17% of assets, up from 16% a quarter earlier, followed by Consumer Discretionary and Industrials.
On the sell side, the largest reduction was Merck, an estimated $12.3M trimmed.
- Y-Intercept (HK)'s largest Q1 2024 buy was General Motors: 287,173 shares worth $13M.
- Y-Intercept (HK) added most to Illinois Tool Works in Q1 2024, an estimated $7.03M increase.
- Y-Intercept (HK)'s biggest Q1 2024 reduction was Merck, cutting an estimated $12.3M.
- Y-Intercept (HK) fully exited NVIDIA in Q1 2024, selling an estimated $10.8M.
- Y-Intercept (HK)'s ten largest holdings make up 6.8% of its $1.33B portfolio in Q1 2024.
- Y-Intercept (HK) opened 682 new positions and closed 544 in Q1 2024.
- Y-Intercept (HK)'s portfolio value rose 24% quarter-over-quarter to $1.33B.
Based on Y-Intercept (HK)'s 13F filing for Q1 2024, filed 10 May 2024.